[The use of BCG vaccine in the treatment of surface tumors of the bladder].

The paper presented results of the treatment of 110 patients with vesical surface tumors, 85 of them were postoperatively treated according to the regime suggested by Adolphs and Bastian and slightly modified for patients with relapsing vesical tumors. For the therapeutic or preventive effect (after TUR or transvesical electrical resection of the urinary bladder surface tumors), the authors used for 6 weeks after the operation intravesical instillations of BCG vaccine ("Calgevax", Bulgarian production) in a weekly dose of 120 mg per 50 ml of the serum. Previously, for this purpose intravenous injections of cyclophosphamide had been routinely used in a dose of 700 mg/m2 during 2 postsurgery weeks.

BCG vaccine therapy for treatment of superficial bladder cancer.

A total of 42 patients were involved in the study of the effectiveness of BCG vaccine on superficial bladder tumours. The new Bulgarian vaccine CALGEVAX was administered intravesically in consecutive instillations once weekly and then once monthly for a period of 11 months. For intradermal application the F-70 subcellular preparation was used.